Exagen reports record AVISE CTD volume of ~137k units, reaffirms FY2023 guidance

EXAGEN INC.

2023-FY EPS reported -$1.34 revenue$52,548,000

Record AVISE® CTD testing volume of approx. 137,000 units in FY2023.
Cash balance of $36.5M as of Dec 31, 2023; AR approx. $7M.
Reaffirms FY2023 revenue guidance of at least $50M, non-GAAP adjusted EBITDA of approx. -$20M.
Management points to streamlined operations and revamped expense structure toward profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EXAGEN INC. updated its the full year ended December 31, 2023 guidance (reaffirmed).

Period: the full year ended December 31, 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.

View on SEC.gov

Browse all earnings releases →

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.